Andre M Samuel1, Kyle W Morse1, Yuri A Pompeu1, Avani S Vaishnav1, Catherine Himo Gang1, Han Jo Kim1,2, Sheeraz A Qureshi3,4. 1. Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA. 2. Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA. 3. Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA. sheerazqureshimd@gmail.com. 4. Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA. sheerazqureshimd@gmail.com.
Abstract
PURPOSE: To determine the association of preoperative opioid prescriptions with reoperations and postoperative opioid prescriptions after adult spina deformity (ASD) surgery. With the current opioid crisis, patients undergoing surgery for ASD are at particular risk for opioid-related complications due to significant preoperative disability and surgical morbidity. No previous studies consider preoperative opioids in this population. METHODS: A retrospective cohort study of patients undergoing posterior spinal fusion (7 or more levels) for ASD was performed. All patients had at least 3 years of postoperative follow-up 3 years postoperatively. Prescriptions for 4 different opioid medications (hydromorphone, oxycodone, hydrocodone, and tramadol) were identified within 3 months preoperatively and up to 3 years postoperatively. Multivariate regression was utilized to determine the association of preoperative use with reoperations and with postoperative opioid use, controlling for both patient and surgery-related confounding factors. RESULTS: A total of 743 patients were identified and 59.6% (443) had opioid prescriptions within 3 months preoperatively. Postoperative opioid prescriptions were identified in 66.9% of patients at 12 months postoperatively, and in 54.8% at 36 months postoperatively. The 3-year reoperation rate was 11.0% in patients without preoperative prescriptions, 16.0% in patients with preoperative any opioid prescriptions (P = 0.07), and 34.8% in patients with preoperative hydromorphone prescriptions (P < 0.01). In multivariate analysis, preoperative opioid prescriptions were associated with increased reoperations (odds ratio [OR]: 1.62, P = 0.04), and chronic postoperative opioid use (OR: 4.40, P < 0.01). Preoperative hydromorphone prescriptions had the strongest association with both reoperations (OR: 4.96; P < 0.01) and chronic use (OR: 5.19: P = 0.03). CONCLUSION: In the ASD population, preoperative opioids are associated with both reoperations and chronic opioid use, with hydromorphone having the strongest association. Further investigation of the benefits of preoperative weaning programs is warranted.
PURPOSE: To determine the association of preoperative opioid prescriptions with reoperations and postoperative opioid prescriptions after adult spina deformity (ASD) surgery. With the current opioid crisis, patients undergoing surgery for ASD are at particular risk for opioid-related complications due to significant preoperative disability and surgical morbidity. No previous studies consider preoperative opioids in this population. METHODS: A retrospective cohort study of patients undergoing posterior spinal fusion (7 or more levels) for ASD was performed. All patients had at least 3 years of postoperative follow-up 3 years postoperatively. Prescriptions for 4 different opioid medications (hydromorphone, oxycodone, hydrocodone, and tramadol) were identified within 3 months preoperatively and up to 3 years postoperatively. Multivariate regression was utilized to determine the association of preoperative use with reoperations and with postoperative opioid use, controlling for both patient and surgery-related confounding factors. RESULTS: A total of 743 patients were identified and 59.6% (443) had opioid prescriptions within 3 months preoperatively. Postoperative opioid prescriptions were identified in 66.9% of patients at 12 months postoperatively, and in 54.8% at 36 months postoperatively. The 3-year reoperation rate was 11.0% in patients without preoperative prescriptions, 16.0% in patients with preoperative any opioid prescriptions (P = 0.07), and 34.8% in patients with preoperative hydromorphone prescriptions (P < 0.01). In multivariate analysis, preoperative opioid prescriptions were associated with increased reoperations (odds ratio [OR]: 1.62, P = 0.04), and chronic postoperative opioid use (OR: 4.40, P < 0.01). Preoperative hydromorphone prescriptions had the strongest association with both reoperations (OR: 4.96; P < 0.01) and chronic use (OR: 5.19: P = 0.03). CONCLUSION: In the ASD population, preoperative opioids are associated with both reoperations and chronic opioid use, with hydromorphone having the strongest association. Further investigation of the benefits of preoperative weaning programs is warranted.
Authors: Lauren K Dunn; Sandeep Yerra; Shenghao Fang; Mark F Hanak; Maren K Leibowitz; Siny Tsang; Marcel E Durieux; Edward C Nemergut; Bhiken I Naik Journal: Anesth Analg Date: 2018-07 Impact factor: 5.108
Authors: Nikhil Jain; Khaled Himed; Jeffrey M Toth; Karen C Briley; Frank M Phillips; Safdar N Khan Journal: Spine J Date: 2018-04-20 Impact factor: 4.166
Authors: Dennis Lee; Sheyan Armaghani; Kristin R Archer; Jesse Bible; David Shau; Harrison Kay; Chi Zhang; Matthew J McGirt; Clinton Devin Journal: J Bone Joint Surg Am Date: 2014-06-04 Impact factor: 5.284
Authors: Giovanni Andrea La Maida; Francesco Luceri; Francesco Gallozzi; Marcello Ferraro; Misaggi Bernardo Journal: Eur Spine J Date: 2015-10-06 Impact factor: 3.134
Authors: Hamid Hassanzadeh; Amit Jain; Mostafa H El Dafrawy; Michael C Ain; Addisu Mesfin; Richard L Skolasky; Khaled M Kebaish Journal: Spine (Phila Pa 1976) Date: 2013-04-20 Impact factor: 3.468
Authors: Frederik Taylor Pitter; Matt Sikora; Martin Lindberg-Larsen; Alma Becic Pedersen; Benny Dahl; Martin Gehrchen Journal: Neurospine Date: 2019-07-24